<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Enrolled-Bill" bill-type="olc" dms-id="A1" public-print="no" public-private="public" stage-count="1" star-print="no-star-print"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title> S2338 ENR: United States Anti-Doping Agency Reauthorization Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date></dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form display="yes">
<congress>One Hundred Thirteenth Congress of the United States of America</congress><session display="yes">2d Session</session><enrolled-dateline display="yes">Begun and held at the City of Washington on Friday, the third day of January, two thousand and
			 fourteen</enrolled-dateline><legis-num display="yes">S. 2338</legis-num><current-chamber display="no">IN THE SENATE OF THE UNITED STATES</current-chamber><legis-type display="yes">AN ACT</legis-type><official-title display="yes">To reauthorize the United States Anti-Doping Agency, and for other purposes.</official-title></form><legis-body display-enacting-clause="yes-display-enacting-clause" style="OLC"><section commented="no" display-inline="no-display-inline" id="S1" section-type="section-one"><enum>1.</enum><header display-inline="yes-display-inline">Short title</header><text display-inline="no-display-inline">This Act may be cited as the
		  <quote><short-title>United States Anti-Doping Agency Reauthorization Act</short-title></quote>.</text></section><section commented="no" display-inline="no-display-inline" id="id5A35AFD1FC254879B52B44DE5DCB9A89" section-type="subsequent-section"><enum>2.</enum><header display-inline="yes-display-inline">Prohibit performance-enhancing methods</header><text display-inline="no-display-inline">Section 701 of title VII of the Office of
National Drug Control Policy Reauthorization Act of 2006 (<external-xref legal-doc="usc" parsable-cite="usc/21/2001">21 U.S.C. 2001</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="id67FFE25C78864C5BBC61262C221750E4"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (a), by striking paragraph (4); and</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idBE0E2D9201E64C07B0A568FADD9D6F29"><enum>(2)</enum><text display-inline="yes-display-inline">in subsection (b)—</text><subparagraph commented="no" display-inline="no-display-inline" id="id9AF1207214F24F6FA0752AA79D4ECA02"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraph (1), by inserting <quote>and be recognized worldwide as the independent
			 national anti-doping organization for the United States</quote> after <quote>Committee</quote>;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id68D8F8A57B904D18B32C525F4D5FF005"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (2), by striking <quote>, or performance-enhancing genetic modifications accomplished
through gene-doping</quote> and inserting <quote>or prohibited performance-enhancing methods adopted by the Agency</quote>;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idBE0156A543DD4F7B9E097C45AB4008A3"><enum>(C)</enum><text display-inline="yes-display-inline">in paragraph (3), by striking <quote>, or performance-enhancing genetic modifications accomplished
through gene-doping</quote> and inserting <quote>or prohibited performance-enhancing methods adopted by the Agency</quote>;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id2364B9843A2D4422AB185CF3B9DDD54E"><enum>(D)</enum><text display-inline="yes-display-inline">in paragraph (4), by striking <quote>and the prevention of use of performance-enhancing drugs, or performance-enhancing
genetic modifications accomplished through gene-doping by
United States amateur athletes; and</quote> and inserting <quote>, and the prevention of use by United States amateur athletes of performance-enhancing drugs or
			 prohibited performance-enhancing methods adopted by the Agency.</quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id7112A90410674649A373CEF75934FC31"><enum>(E)</enum><text display-inline="yes-display-inline">by striking paragraph (5).</text></subparagraph></paragraph></section><section commented="no" display-inline="no-display-inline" id="idAE567C321CBD4BF29D2DDE71543ED884" section-type="subsequent-section"><enum>3.</enum><header display-inline="yes-display-inline">Authorization of appropriations</header><text display-inline="no-display-inline">Section 703 of title VII of the Office of
National Drug Control Policy Reauthorization Act of 2006 (<external-xref legal-doc="usc" parsable-cite="usc/21/2003">21 U.S.C. 2003</external-xref>) is amended to read as
			 follows:</text><quoted-block display-inline="no-display-inline" id="id0EF0A1EFB4194B42BBF2D4EA1B7E9B36" style="OLC"><section commented="no" display-inline="no-display-inline" id="idA19E869EEBB3459490ED5DBEB40BCC59" section-type="subsequent-section"><enum>703.</enum><header display-inline="yes-display-inline">Authorization of appropriations</header><text display-inline="no-display-inline">There are authorized to be appropriated to the United States
Anti-Doping Agency—</text><paragraph commented="no" display-inline="no-display-inline" id="idB5E00E0013A04377850168391169A528"><enum>(1)</enum><text display-inline="yes-display-inline">for fiscal year 2014, $11,300,000;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idC32D83DBA49A4F478C8286AF4070854D"><enum>(2)</enum><text display-inline="yes-display-inline">for fiscal year 2015, $11,700,000;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id1C6F7C153ED446F495D0FD0F7323A35B"><enum>(3)</enum><text display-inline="yes-display-inline">for fiscal year 2016, $12,300,000;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id7C191027B347483692BD8763BCBCEC0C"><enum>(4)</enum><text display-inline="yes-display-inline">for fiscal year 2017, $12,900,000;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id1CF7C77D7BF3482E90315DF820970A3B"><enum>(5)</enum><text display-inline="yes-display-inline">for fiscal year 2018, $13,500,000;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id962236106A314BFDB98798ACE68A7DEF"><enum>(6)</enum><text display-inline="yes-display-inline">for fiscal year 2019, $14,100,000; and</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id318AA7D7B17E40B79DB888401DB36197"><enum>(7)</enum><text display-inline="yes-display-inline">for fiscal year 2020, $14,800,000.</text></paragraph></section><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body><attestation><attestation-group><attestor display="no"></attestor><role>Speaker of the House of Representatives</role></attestation-group><attestation-group><attestor display="no"></attestor><role>Vice President of the United States and President of the Senate</role></attestation-group></attestation></bill>


